Published in J Cell Biochem on November 01, 2011
Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med (2015) 1.71
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol (2012) 0.91
N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways. Mol Pharmacol (2012) 0.88
Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. Inflamm Res (2012) 0.82
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? Psychopharmacology (Berl) (2015) 0.81
The endocannabinoid N-arachidonoyl glycine (NAGly) inhibits store-operated Ca2+ entry by preventing STIM1-Orai1 interaction. J Cell Sci (2012) 0.80
N-Arachidonoyl glycine suppresses Na⁺/Ca²⁺ exchanger-mediated Ca²⁺ entry into endothelial cells and activates BK(Ca) channels independently of GPCRs. Br J Pharmacol (2013) 0.78
N-Amino acid linoleoyl conjugates: anti-inflammatory activities. Bioorg Med Chem Lett (2011) 0.78
The cannabinoid acids, analogs and endogenous counterparts. Bioorg Med Chem (2014) 0.76
GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow Transplantation. PLoS One (2015) 0.75
Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity. Life Sci (2012) 0.75
Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med (1999) 6.91
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
Acute inflammation. A review. Am J Pathol (1977) 2.06
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res (2010) 1.95
The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol (1972) 1.86
Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun (2006) 1.79
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci (2010) 1.78
Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72
The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem (2009) 1.28
T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci (2009) 1.18
Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology (2007) 1.17
Arachidonic acid metabolism: role in inflammation. Z Rheumatol (1991) 1.09
Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J (2009) 1.07
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (2004) 1.05
N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol (2010) 1.04
Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett (2005) 1.02
Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol (2009) 1.01
Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem (2007) 0.97
Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta (1998) 0.92
The elmiric acids: biologically active anandamide analogs. Neuropharmacology (2007) 0.88
Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J Biol Chem (2003) 1.94
Regulation of the PTEN phosphatase. Gene (2006) 1.69
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med (2010) 1.55
PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci (2002) 1.43
Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest (2011) 1.41
Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem (2009) 1.35
Why is PTEN an important tumor suppressor? J Cell Biochem (2007) 1.31
PTEN phosphatase selectively binds phosphoinositides and undergoes structural changes. Biochemistry (2008) 1.28
PTEN enters the nucleus by diffusion. J Cell Biochem (2005) 1.28
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res (2010) 1.23
EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol (2008) 1.18
A novel phosphatidylinositol(3,4,5)P3 pathway in fission yeast. J Cell Biol (2004) 1.14
Membrane association of the PTEN tumor suppressor: molecular details of the protein-membrane complex from SPR binding studies and neutron reflection. PLoS One (2012) 1.12
Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett (2010) 1.12
PTEN regulation of neural development and CNS stem cells. J Cell Biochem (2003) 1.09
Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J (2009) 1.07
Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) (2013) 1.00
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett (2010) 0.98
Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol (2006) 0.97
Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem (2007) 0.97
Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther (2010) 0.94
Nitric oxide-mediated inhibition of Hdm2-p53 binding. Biochemistry (2002) 0.94
A mutant form of PTEN linked to autism. Protein Sci (2010) 0.93
Isolation of immortalized, INK4a/ARF-deficient cells from the subventricular zone after in utero N-ethyl-N-nitrosourea exposure. J Neurosurg (2005) 0.91
Doublecortin is preferentially expressed in invasive human brain tumors. Acta Neuropathol (2005) 0.87
PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism. Adv Exp Med Biol (2013) 0.85
Profiling of genes expressed by PTEN haploinsufficient neural precursor cells. Mol Cell Neurosci (2003) 0.81
Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis. Neurobiol Dis (2004) 0.81
A method for clonal analysis of epidermal growth factor-responsive neural progenitors. J Neurosci Methods (2002) 0.81
Novel functional interactions between Trk kinase and p75 neurotrophin receptor in neuroblastoma cells. J Neurosci Res (2003) 0.78
Differentiation prevents assessment of neural stem cell pluripotency after blastocyst injection. Stem Cells (2004) 0.75